Tonix Pharmaceuticals Holding Corp. (TNXP)
$13.09
$-0.28
(-2.09%)
As on 04-Sep-2026 13:36EDT
Market cap
$233 Mln
Revenue (TTM)
$29 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-14.5
-
Face value
--
-
Shares outstanding
17,151,024
10 Years Aggregate
CFO
$-496.64 Mln
EBITDA
$-558.35 Mln
Net Profit
$-564.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
| -16.2 | 22.7 | 14.8 | -52.7 | -84.0 | -87.6 | -84.3 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
| -52.6 | -97.3 | -83.6 | -46.7 | -42.3 | -94.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
13.1 | 233.1 | 29.1 | -159.7 | -548.6 | -68.3 | -- | 1.0 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Tonix Pharmaceuticals Holding (TNXP)
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United... States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey. Read more
-
Co-Founder, President, CEO & Chairman
Dr. Seth Lederman M.D.
-
Co-Founder, President, CEO & Chairman
Dr. Seth Lederman M.D.
-
Headquarters
Berkeley Heights, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Tonix Pharmaceuticals Holding (TNXP)
What is the current share price of Tonix Pharmaceuticals Holding Corp (TNXP) Today?
The share price of Tonix Pharmaceuticals Holding Corp (TNXP) is $13.09 (NASDAQ) as of 04-Sep-2026 13:36 EDT. Tonix Pharmaceuticals Holding Corp (TNXP) has given a return of -84.01% in the last 3 years.
What is the current PB & PE ratio of Tonix Pharmaceuticals Holding Corp (TNXP)?
Since, TTM earnings of Tonix Pharmaceuticals Holding Corp (TNXP) is negative, P/E ratio is not available.
The P/B ratio of Tonix Pharmaceuticals Holding Corp (TNXP) is 1.05 times as on 28-Aug-2026, a 80 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.07 |
0.54 |
2024 |
-0.01 |
0.01 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Tonix Pharmaceuticals Holding Corp (TNXP)?
The 52-week high and low of Tonix Pharmaceuticals Holding Corp (TNXP) are Rs 31.28 and Rs 9.40 as of 06-Sep-2026.
What is the market cap of Tonix Pharmaceuticals Holding Corp (TNXP)?
Tonix Pharmaceuticals Holding Corp (TNXP) has a market capitalisation of $ 233 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Tonix Pharmaceuticals Holding Corp (TNXP)?
Before investing in Tonix Pharmaceuticals Holding Corp (TNXP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.